# Relay Therapeutics **Source:** https://geo.sig.ai/brands/relay-therapeutics **Vertical:** Life Sciences & BioTech **Subcategory:** AI Drug Discovery **Tier:** Emerging **Website:** relaytx.com **Last Updated:** 2026-04-14 ## Summary Cambridge MA precision oncology biotech using Dynamo platform to exploit protein motion for drug design; lead asset RLY-2608 targets PI3Kα in breast cancer. ## Company Overview Relay Therapeutics was founded in 2016 in Cambridge, Massachusetts, emerging from research at MIT and D.E. Shaw Research. The company is built around its Dynamo platform, which integrates computational protein motion modeling (molecular dynamics simulations) with structural biology and medicinal chemistry to design small-molecule drugs that exploit the dynamic conformational states of disease-relevant proteins—a dimension traditional structure-based drug design ignores.\n\nRelay's lead program, RLY-2608, is a first-in-class allosteric, mutant-selective PI3Kα inhibitor for advanced breast cancer patients with PI3KCA mutations. Unlike approved PI3Kα inhibitors that cause metabolic toxicity by inhibiting wild-type PI3Kα in normal tissues, RLY-2608 selectively targets the mutant form. The compound has shown early clinical promise including objective responses in patients who progressed on prior alpelisib, supporting a differentiated profile. Additional programs target FGFR2 and SHP2 in solid tumors.\n\nRelay has raised over $1.2 billion in equity financing and holds substantial cash reserves. The company is conducting multiple clinical trials and building a pipeline that validates its Dynamo-guided discovery approach. Though revenue-stage remains early, Relay represents a leading example of next-generation computational oncology companies seeking to turn protein dynamics insights into selective, differentiated medicines. ## Frequently Asked Questions ### What is the Dynamo platform? Dynamo integrates molecular dynamics simulations, structural biology, and medicinal chemistry to design drugs that exploit protein motion and conformational states—going beyond static crystal structure-based design. ### What is RLY-2608 and why is it differentiated? RLY-2608 is a mutant-selective allosteric PI3Kα inhibitor for breast cancer that targets only the PI3KCA mutant form, avoiding the metabolic toxicity caused by inhibiting wild-type PI3Kα in normal tissues. ### Who founded Relay Therapeutics? Relay was founded in 2016 by a team including scientists from MIT and D.E. Shaw Research, combining cutting-edge molecular dynamics computing with drug discovery expertise. ### What is Relay Therapeutics' approach to drug discovery? Relay Therapeutics uses its proprietary Dynamo platform to study proteins in their dynamic, moving states rather than as static crystal structures. By modeling how proteins flex and change shape over time, Relay can identify drug binding sites and design molecules that only interact with specific conformational states — enabling more selective and less toxic drugs. ### What stage is RLY-2608 in clinical development? RLY-2608 is a PI3Kα inhibitor for breast cancer in Phase II clinical trials, with interim data showing meaningful responses in PIK3CA-mutant breast cancer patients. Relay has reported RLY-2608 achieving better tolerability than prior PI3Kα inhibitors like alpelisib due to its mutant-selective mechanism. ### How much has Relay Therapeutics raised? Relay Therapeutics went public via IPO in 2020, raising approximately $414 million. As a public company (NASDAQ: RLY), it has continued to fund operations through equity raises. The company was founded with backing from Third Rock Ventures and other leading healthcare investors. ### What other drug programs is Relay advancing? Beyond RLY-2608, Relay is pursuing programs in FGFR2 and SHP2 inhibition, applying Dynamo to identify mutation-selective opportunities across oncology targets. The platform is designed to be a repeatable engine for identifying conformational selectivity opportunities across diverse disease-relevant proteins. ### How does Relay's platform compete with other computational drug discovery companies? Relay differentiates from pure computational platforms (Schrödinger, Recursion) by deeply integrating wet lab structure biology and medicinal chemistry with its computational capabilities — the Dynamo platform is validated by experimental data throughout, not just in silico predictions, which Relay believes leads to higher-quality clinical drug candidates. ### What is Relay Therapeutics' investment and financial position? Relay Therapeutics has raised over $700 million in public equity since its 2020 IPO on Nasdaq (ticker: RLAY), with a cash position supporting multiple clinical programs through key data readouts. The company operates at a pre-revenue R&D stage typical for clinical-stage biotech companies. ### What is an allosteric inhibitor and why is it significant for RLY-2608? An allosteric inhibitor binds to a site away from the protein's active site, changing the protein's shape to reduce its activity — often achieving greater selectivity than active-site competitive inhibitors. RLY-2608's allosteric mechanism allows it to selectively inhibit only mutant PI3Kα forms while sparing wild-type PI3Kα activity essential for healthy metabolism. ### What other programs does Relay Therapeutics have beyond RLY-2608? Relay's pipeline includes SHP2 inhibitors for cancer, a FGFR2 program for cholangiocarcinoma, and additional oncology targets identified through the Dynamo platform. The company focuses on targets with significant protein motion and conformational complexity where structure-based design alone has historically failed. ### How does Relay Therapeutics' Dynamo platform use molecular dynamics? Molecular dynamics simulations model proteins as flexible, dynamic structures evolving over time rather than static snapshots from crystallography. Relay's Dynamo platform runs supercomputer-scale MD simulations to reveal allosteric binding sites and conformational states that only exist transiently — exposing drug-binding opportunities invisible to conventional static structure-based drug design. ### What clinical stage is Relay Therapeutics at? Relay has multiple programs in Phase 1/2 clinical trials, with RLY-2608 in PI3Kα-mutant breast cancer showing early clinical signals in combination with fulvestrant. The company is advancing toward Phase 2 dose-expansion cohorts to establish efficacy endpoints for regulatory purposes. ## Tags b2b, startup, healthtech, ai-powered, platform --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*